Candesartan cilexetil loaded nanodelivery systems for improved oral bioavailability

Ther Deliv. 2017 Feb;8(2):79-88. doi: 10.4155/tde-2016-0063.

Abstract

Candesartan cilexetil (CC), an antihypertensive drug, has low oral bioavailability due to poor solubility and hepatic first-pass metabolism. These are major limitations in oral delivery of CC. Several approaches are known to reduce the problems of solubility and improve the bioavailability of CC. Among various approaches, nanotechnology-based delivery of CC has potential to overcome the challenges associated with the oral administration. This review focuses on various nano-based delivery systems available and tried for improving the aqueous solubility, dissolution and consequently bioavailability of CC upon oral administration. Of all, solid lipid nanoparticles appear to be promising delivery system, based on current reported results, for delivery of CC, as this system improved the oral bioavailability and possessed prolonged pharmacodynamic effect.

Keywords: candesartan cilexetil; oral bioavailability; solid lipid nanoparticles.

Publication types

  • Review

MeSH terms

  • Administration, Oral
  • Benzimidazoles / pharmacokinetics*
  • Biological Availability
  • Biphenyl Compounds / pharmacokinetics*
  • Drug Delivery Systems*
  • Humans
  • Nanoparticles*
  • Solubility
  • Tetrazoles / pharmacokinetics*

Substances

  • Benzimidazoles
  • Biphenyl Compounds
  • Tetrazoles
  • candesartan cilexetil